Arena Pharmaceuticals Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Arena Pharmaceuticals Inc
Access all reports
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company offers BELVIQ, a serotonin 2C receptor agonist approved for marketing in the United States; Belviq XR, an extended-release formulation of lorcaserin; APD334 that is in phase II clinical study for treating autoimmune diseases, including ulcerative colitis and Crohn's disease; APD371 for the treatment of patients with pain associated with Crohn's disease; and APD811, which is in phase I clinical stage to treat pulmonary arterial hypertension. It also develops ralinepag (APD811), which has completed phase II clinical stage for the treatment of pulmonary arterial hypertension.
Latest articles
)
Moncler: From the Mountains to the Runway
The story of Moncler, all the way from its beginnings in the Alps to its journey to some of the most prestigious runways in the world.
16 Apr 2025
)
eToro: Innovation, Growth, and IPO Plans
eToro was founded in 2007 and has grown into a global trading platform with over 40 million users and an extensive offering across several asset classes.
10 Apr 2025
)
Yum! Brands: The Company Behind Pizza Hut, KFC, and Taco Bell
Yum! Brands started at PepsiCo in the 1970s and is home to some of the most well-known brands in the world, such as Pizza Hut, KFC, and Taco Bell.
9 Apr 2025
Ticker symbol
ARNA
Country
🇺🇸 United States